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Paclitaxel is a potent anticancer drug with proven activity against a
number of human solid tumours and has become standard treatment
as single agent or in combination chemotherapy for the management
of advanced breast, ovarian and non-small cell lung cancer
(Rowinsky and Donehower, 1995; Natale, 1998). The intravenous
(i.v.) administration of paclitaxel is, however, inconvenient for
patients and associated with significant and unpredictable side-
effects. Severe hypersensitivity reactions have been observed after
i.v. infusion of paclitaxel and it is now well established that the phar-
maceutical vehicle Cremophor EL contributes largely to this effect
(Dye and Watkins, 1980; Weiss et al, 1990). Oral administration of
paclitaxel is very attractive, because it is convenient and practical
for patients and it may circumvent systemic exposure to the toxic
vehicle Cremophor EL. Furthermore, oral administration may
enable development of chronic treatment schedules resulting in
sustained plasma concentrations above a pharmacological relevant
threshold level. For paclitaxel a strong positive relationship has been
reported between duration of the paclitaxel plasma concentration
above 0.05 µM or 0.1 µM and myelosuppression (Huizing et al,
1993; Gianni et al, 1995; Ohtsu et al, 1995). In addition, Huizing et
al (1997) have found, in a retrospective phase I/II study in patients
with advanced non-small cell lung cancer, a significant survival
benefit in patients who had an exposure duration of paclitaxel above
0.1 µM of more than 15 hours compared with patients who had a
shorter duration of exposure above this cut off level. However, these
data need confirmation in a prospective study. In view of increasing
costs of anticancer therapy, oral treatment of paclitaxel is attractive,
as oral administration eliminates the need for hospitalization, physi-
cian and nursing assistance and infusion equipment. 
Up to now, oral administration of paclitaxel has not appeared
feasible because of the low oral bioavailability (<10%) of the drug.
Preclinical studies in mice have shown that the low oral bioavail-
ability is due to efficient transport of the drug by the multidrug
efflux pump P-glycoprotein (P-gp) abundantly present in the
gastrointestinal tract (Schinkel, 1997; Van Asperen et al, 1998a).
This became clear when we investigated the oral uptake of pacli-
taxel in mdrl a knock-out mice, which lack functional P-gp activity
in the gut (Sparreboom et al, 1997). This mouse model revealed
significant bioavailability of orally administered paclitaxel. In
wild-type mice good bioavailability of orally administered pacli-
taxel was achieved when the drug was combined with cyclosporin
A (CsA) or the cyclosporin analogue SDZ PSC 833, both effica-
cious blockers of P-gp (Van Asperen et al, 1997, 1998b). Based on
our preclinical experiments we recently demonstrated the feasi-
bility of oral administration of paclitaxel in cancer patients by
concomitant administration of CsA. Co-administration of CsA
resulted in a significant increase of at least 7-fold in the oral
bioavailability of paclitaxel and plasma concentrations increased
from negligible to therapeutic levels (Meerum Terwogt et al, 1998,
1999). In this study we tested the P-gp blocker GF120918 in
combination with oral paclitaxel. GF120918, an acridone carbo-
xamide derivative, is a potent inhibitor of P-gp. In in vitro models
Co-administration of GF120918 significantly increases
the systemic exposure to oral paclitaxel in cancer
patients 
MM Malingré1,2, JH Beijnen1,2,4, H Rosing2, FJ Koopman2, RC Jewell3, EM Paul3, WW Ten Bokkel Huinink1
and JHM Schellens1,4
1Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, 
The Netherlands; 2Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, 
The Netherlands; 3Glaxo Wellcome, Five Moore Drive, Research Triangle Park, NC, 27709, USA; 4Division of Drug Toxicology, Faculty of Pharmacy, Utrecht
University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
Summary Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump
P-glycoprotein (P-gp). We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration
of the P-gp blocker cyclosporin A (CsA). Now we tested the potent alternative orally applicable non-immunosuppressive P-gp blocker GF120918.
Six patients received one course of oral paclitaxel of 120 mg/m2 in combination with 1000 mg oral GF120918 (GG918, GW0918). Patients
received intravenous (i.v.) paclitaxel 175 mg/m2 as a 3-hour infusion during subsequent courses. The mean area under the plasma
concentration–time curve (AUC) of paclitaxel after oral drug administration in combination with GF120918 was 3.27 ± 1.67 µ M.h.In our previously
performed study of 120 mg/m2 oral paclitaxel in combination with CsA the mean AUC of paclitaxel was 2.55± 2.29 µ M.h.After i.v. administration of
paclitaxel the mean AUC was 15.92± 2.46 µ M.h. The oral combination of paclitaxel with GF120918 was well tolerated. The increase in systemic
exposure to paclitaxel in combination with GF120918 is of the same magnitude as in combination with CsA. GF120918 is a good and safe
alternative for CsA and may enable chronic oral therapy with paclitaxel. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: paclitaxel; oral administration; bioavailability; P-glycoprotein; GF120918 
42
Received 22 May 2000 
Revised 31 August 2000 
Accepted 13 September 2000
Correspondence to: MM Malingré 
British Journal of Cancer (2001) 84(1), 42–47
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1543, available online at http://www.idealibrary.com on  http://www.bjcancer.comIncreased oral bioavailability of paclitaxel by GF120918 43
British Journal of Cancer (2001) 84(1), 42–47 © 2001 Cancer Research Campaign
of P-gp inhibition, GF120918 is active at concentrations around
20 nM, which is about 100 fold more potent than CsA (Hyafil et al,
1993). Importantly, clinical studies of GF120918 with doses up to
1000 mg bid have shown no significant toxicities or side-effects of
the drug (Ferry et al, 1998; Planting et al, 1998); it may therefore
be a better candidate for clinical use, especially for repeated
administration, than the immunosuppressive drug CsA. Based on
the promising results of our preclinical studies with oral paclitaxel
plus GF120918, revealing an approximately 7-fold increase in the
systemic exposure in wild-type mice (Van Tellingen et al, 2000),
we initiated this clinical study of orally administered paclitaxel in
combination with oral GF120918. 
PATIENTS AND METHODS 
Patient population 
Patients with a histologically confirmed cancer refractory to
current therapies were eligible for the study. Previous radiotherapy
or chemotherapy other than taxoid therapy was allowed, provided
that the last treatment was at least four weeks prior to study entry
and any resulting toxicities were resolved. Eligibility criteria
included acceptable bone marrow function (white blood cells
> 3.0 × 10 9 l–1; platelets > 100 × 109 l–1), liver function (serum
bilirubin ≤ 25µmol l–1;serum albumin ≥ 25 g l–1), kidney function
(serum creatinine ≤ 160µmol l–1 or clearance ≥ 50 ml min–1) and
a World Health Organization (WHO) performance status ≤ 2.
Patients were not eligible if they suffered from uncontrolled infec-
tious disease, neurologic disease, bowel obstruction or sympto-
matic brain metastases. Other exclusion criteria were concomitant
use of known P-gp inhibitors and chronic use of H2-receptor
antagonists or proton pump inhibitors. The study protocol was
approved by the Medical Ethics Committee of the Institute and all
patients gave written informed consent. 
Study design 
Six patients received at one occasion paclitaxel orally 120 mg/m2
in combination with a single oral dose of GF120918 of 1000 mg.
At another occasion patients received intravenous (i.v.) paclitaxel
administered as a 3-hour infusion at a dose of 175 mg/m2. The oral
and i.v. course were randomized. If it was considered to be in their
best interest, patients continued on a 3-weekly schedule of i.v.
paclitaxel. An oral paclitaxel dose of 120 mg/m2 was selected for
safety reasons because preclinical data of oral paclitaxel revealed
that co-administration of a P-gp inhibitor and an oral paclitaxel
dose can result in higher systemic exposure than after i.v. adminis-
tration of the same dose (Van Asperen et al, 1997). An oral
GF120918 dose of 1000 mg was selected because this dose was
well tolerated and was expected to produce significant local P-gp
blockade (Ferry et al, 1998; Planting et al, 1998). The i.v. for-
mulation of paclitaxel (Taxol®, paclitaxel 6 mg ml–1, dissolved 
in Cremophor EL and ethanol 1:1 v/v, Bristol-Myers Squibb,
Syracuse, NY, USA) was used for both i.v. and oral administration
of paclitaxel. GF120918 (GG918, GW0918, Glaxo Wellcome,
Research Triangle Park, NC, USA) (100 mg tablets) was ingested
one hour prior to oral paclitaxel administration. As the absorption
of GF120918 is improved after intake of a meal, the drug was in-
gested 30 minutes after a standard light breakfast. Patients fasted
for two hours following oral paclitaxel intake. To prevent nausea and
vomiting patients received oral granisetron 1 mg approximately 
1 hour prior to oral paclitaxel administration. At all i.v. occasions,
patients were premedicated with dexamethasone 20 mg orally 
12 and 6 hours prior to, clemastine 2 mg i.v. 30 minutes 
prior to and cimetidine 300 mg i.v. shortly prior to paclitaxel
administration. 
Patient evaluation 
Pretreatment evaluation included a complete medical history and
complete physical examination. Before each course, an interim
history including concomitant medications taken, toxicities and
performance status were registered and a physical examination
was performed. Haematology was checked twice weekly after
course 1 and 2 and weekly after subsequent courses. Blood
chemistries including liver and renal function, serum electrolytes,
total protein and albumin and glucose levels were checked weekly.
All toxicities observed were graded according to the National
Cancer Institute Common Toxicity Criteria (NCI CTC) (National
Cancer Institute, 1988). Dose-limiting toxicities (DLT) were
defined as grade 4 granulocytopenia of a duration of > 5 days,
grade 4 thrombocytopenia of any duration or any grade 3/4 non-
haematological toxicity except untreated nausea and vomiting.
Tumour measurements were performed every other cycle, but
initially after the first 2 i.v. courses. Responses were evaluated
according to the WHO criteria (World Health Organization, 
1979). 
Sample collection and analysis 
Blood samples for pharmacokinetic analyses were collected
during course 1 and course 2. For plasma paclitaxel and metabolite
concentrations, blood samples of 5 ml each were collected at 0, 15,
30, 45, 60, 75, 90 minutes and 2, 3, 4, 7, 10, 24, 30 and 48 hours
after oral intake of paclitaxel. During i.v. administration of pacli-
taxel a previously established limited sampling model was applied
using 2 plasma concentration–time points at 1 and 8 hours after the
end of the 3-hour infusion (Huizing et al, 1995a). Blood samples
were centrifuged, plasma was separated and samples were
immediately stored at –20˚C until analysis. Paclitaxel and meta-
bolite concentrations were determined using a validated high 
performance liquid chromatography (HPLC) assay (Huizing et al,
1995b). 
For GF120918 concentrations, blood samples of 7 ml each were
collected on ice at 0, 30, 60, 90 minutes and 2, 3, 4, 5, 8, 11, 25, 31
and 49 hours after GF120918 intake. Blood samples were
centrifuged at 4˚C, plasma was separated and samples were imme-
diately stored at –20˚C until analysis. GF120918 concentrations
were determined using a validated HPLC assay (Witherspoon et
al, 1996). 
Pharmacokinetic analysis 
Non-compartmental pharmacokinetic methods were applied to
process the results (Gibaldi and Perrier, 1982). For orally adminis-
tered paclitaxel, the maximal drug concentration (Cmax) and time 
to maximal drug concentration (Tmax) were obtained directly 
from the experimental data. The area under the plasma paclitaxel
concentration–time curve was calculated by the trapezoidal rule up
to the last measured concentration–time point (AUCt) and extra-
polated to infinity using the terminal rate constant k (AUC). The
time above the threshold concentrations of 0.05 µM and 0.1 µM (T > 0.05 µM, T > 0.1 µM) was determined using linear interpola-
tion. For i.v. administered paclitaxel the parameters AUC and T >
0.1 µM were determined using our previously established limited
sampling model (Huizing et al, 1995a). Bioavailability of oral
paclitaxel was calculated as the ratio of the AUC after oral and
after i.v. administration with a correction for the difference in
dose. Statistical analysis of the data was performed using the
nonparametric Mann-Whitney U-test. The a priori level of signifi-
cance was P = 0.05. 
RESULTS 
Patients and treatment 
A total of six patients (3 males/3 females) was enrolled in the
study. At study entry the median age of the patients was 58 years
(range 49 to 65) with a median performance status of 1 (range
0–1). Primary tumour types included breast (1), non-small cell
lung cancer (NSCLC) (2) and adenocarcinoma of unknown
primary site (3). Three patients received oral paclitaxel in
combination with GF120918 during the first course and i.v. pacli-
taxel during course 2. The other three patients received i.v.
paclitaxel during course 1 and oral paclitaxel in combination with
GF120918 during course 2. During all subsequent courses patients
received i.v. administered paclitaxel. 
The oral combination of paclitaxel and GF120918 was very
well tolerated. No significant side-effects were seen after one
course of oral paclitaxel in combination with GF120918.
Haematological toxicities after oral administration of paclitaxel
consisted of anaemia grade 1 (3 pts) and 2 (1 pt), which was often
pre-existing, leukocytopenia grade 1 (1 pt) and 3 (1 pt) and granu-
locytopenia grade 2 (1 pt). Non-haematological toxicities after
oral intake consisted of nausea grade 1 (1 pt) and 2 (1 pt), vomiting
grade 2 (1 pt), arthralgia/myalgia grade 1 (2 pts), stomatitis grade
1 (1 pt), skin reactions grade 1 (1 pt), alopecia grade 1 (1 pt) and
fatique grade 2 (1 pt). Toxicities clearly associated with GF120918
administration were not observed. During subsequent treatment
with i.v. paclitaxel a toxicity pattern common to paclitaxel 
developed with anaemia, leukocytopenia, granulocytopenia, arthralgia/
myalgia, nausea, vomiting, stomatitis, skin reactions, neuro-
toxicity and fatique as main toxicities. In this study no tumour
responses were observed. 
Pharmacokinetics 
Table 1 summarizes the main pharmacokinetic parameters of oral
and i.v. administered paclitaxel. The mean AUC value of pacli-
taxel in patients who received oral paclitaxel in combination with
GF120918 was 3.27 ± 1.67 µ M.h. There was no statistically
significant difference in the paclitaxel AUC values between the
patients who started with oral paclitaxel and GF120918 and those
who received the drugs during the second course. The mean
plasma concentration–time curve of oral paclitaxel in combination
with GF120918 is shown in Figure 1. After i.v. administration, the
mean AUC value of paclitaxel was 15.92 ± 2.46 µ M.h which is in
good agreement with earlier data (Huizing et al, 1993, 1997). The
oral bioavailability of paclitaxel, calculated as the AUC after oral
administration (120 mg/m2) divided by the AUC after i.v. adminis-
tration (175 mg/m2) with a correction for the difference in dose,
was 30 ± 15%. However, because of the pronounced non-linear
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Figure 1 Plasma concentration–time curve of oral paclitaxel at a dose of
120 mg/m2 in combination with 1000 mg oral GF120918 (n = 6). Data are
represented as means ± SD
Table 1 Pharmacokinetics of oral paclitaxel (120 mg/m2) in combination with GF120918 (1000 mg) and i.v. paclitaxel (175 mg/m2 administered as a 3-hour
infusion)
Oral paclitaxel i.v. paclitaxel
Patient Course AUC Cmax Tmax T > 0.1 µ M T > 0.05 µ M F AUC T > 0.1 µ M
(µ M.h) (µ M) (h) (h) (h) (%) (µ M.h) (h)
1 2 4.56 0.48 3.0 8.8 15.1 36 18.59 22.3
2 1 4.36 0.33 3.0 15.3 25.0 49 13.01 12.1
3 1 5.23 0.62 3.0 9.6 23.9 41 18.59 20.9
4 2 1.11 0.17 1.9 2.6 3.9 11 14.90 13.8
5 2 1.92 0.20 3.1 4.2 6.1 17 16.87 16.6
6 1 2.41 0.33 3.0 4.3 6.7 26 13.54 13.9
mean 3.27 0.36 2.8 7.5 13.5 30 15.92 16.6
SD 1.67 0.17 0.5 4.7 9.3 15 2.46 4.2
AUC, area under the plasma concentration–time curve; Cmax, maximal drug concentration; Tmax, time to maximal drug concentration; T > 0.1 µ M, time above 
0.1 µ M; T > 0.05 µ M, time above 0.05 µ M; F, bioavailability.pharmacokinetics of i.v. paclitaxel (Gianni et al, 1995; Sparre-
boom et al, 1996b), this calculation results in an underestimation
of the true bioavailability. In a dose-finding study performed by
Huizing et al (1997), a mean AUC of i.v. paclitaxel at a dose of
125 mg/m2 of 6.8 µM.h was reported. Recalculation of the
bioavailability of 120 mg/m2  orally administered paclitaxel
applying the dose-adjusted AUC found by Huizing et al (1997)
provides a value of 50% for the oral bioavailability of paclitaxel in
combination with GF120918. 
The mean AUC and AUCt values of GF120918 were 13747 ±
9733 ng.h ml–1 and 9428 ± 5431 ng.h ml–1, respectively. AUCt
values have been calculated because of the high per cent of the AUC
extrapolated in two patients, i.e. 56% and 54% of the area under
the curve. The mean maximum concentration of GF120918 was
434 ± 267 ng ml–1 which was reached at 7.7 ± 2.5 hours after intake. 
In Table 2 a comparison is made between the plasma pharmaco-
kinetic parameters of paclitaxel after oral administration in combi-
nation with GF120918 and those of oral paclitaxel at the same
dose but in combination with CsA. The latter data were taken from
a study that has been performed previously at our Institute
(Malingré et al, 2000). The mean paclitaxel AUC value in patients
who received oral paclitaxel combined with GF120918 was 3.27 ±
1.67 µM.h and 2.55 ± 2.29 µM.h in patients who received oral
paclitaxel in combination with CsA (not statistically significant).
For the paclitaxel metabolites6α -hydroxypaclitaxel, 3′ p-hydroxy-
paclitaxel and 6α , 3′ p-dihydroxypaclitaxel mean AUCt values
after oral drug administration in combination with GF120918 
(n = 5) were 0.40 ± 0.36, 0.36 ± 0.39 and 0.24 ± 0.34 µM.h
respectively. Metabolite data of one patient could not be deter-
mined due to (unknown) interfering compounds in the analytical
assay. After oral paclitaxel combined with CsA (n = 3) these
values were 1.69 ± 2.71, 0.48 ± 0.50 and 0.88 ± 1.48 µM.h, respec-
tively (these metabolite data have not been published before). The
AUCt ratio for the metabolites 6α -hydroxypaclitaxel and 3′ p-
hydroxypaclitaxel was 1.1 (0.40/0.36) after oral drug administra-
tion with GF120918, whereas this ratio was 3.5 (1.69/0.48) when
paclitaxel was combined with CsA. AUCt values have been calcu-
lated because extrapolation of the AUC could not be performed
properly due to erratic profiles and the limited time that the
metabolites could be detected. 
DISCUSSION 
We have recently demonstrated that the poor oral bioavailability of
paclitaxel can be increased at least 7-fold by co-administration of
the P-gp blocker CsA (Meerum Terwogt et al, 1998, 1999). In this
study we tested the potent alternative non-immunosuppressive 
P-gp blocker GF120918 in combination with oral paclitaxel. 
The mean AUC value of paclitaxel achieved after oral adminis-
tration in combination with GF120918 was 3.27 ± 1.67 µM.h,
which is comparable to the AUC value achieved after oral pacli-
taxel administration in combination with CsA, i.e. 2.55 ± 2.29
µM.h (Malingré et al, 2000). Therefore, GF120918 is a good
alternative for CsA in enhancing the oral bioavailability of pacli-
taxel. In both studies toxicities clearly related to the single dose
administration of GF120918 or CsA were not observed. As the
feasibility of oral paclitaxel administration will result in repeated
dosing of either one of the P-gp blockers, the non-immunosuppres-
sive agent GF120918 may be a better candidate for clinical use
than the immunosuppressive drug CsA. 
Preclinical studies of GF120918 with P-gp knock-out mice (Van
Tellingen et al, 2000), which lack functional activity of P-gp, have
shown similar pharmacokinetics of oral paclitaxel with or without
co-administration of GF120918 and therefore indicate that the
increase in systemic exposure to paclitaxel following GF120918
co-administration is solely due to blockade of P-gp. Our preclin-
ical studies of CsA with wild-type mice (Van Asperen et al,
1998b), however, have shown higher AUC values of oral pacli-
taxel compared to those in P-gp knock-out mice without CsA
(Sparreboom et al, 1997), indicating interference of CsA in uptake
and elimination pathways of orally administered paclitaxel other
than mediated by P-gp. For CsA, an important factor that may
contribute to the increase in systemic exposure to oral paclitaxel is
inhibition of paclitaxel metabolism; both paclitaxel and CsA are
substrates for the cytochrome P450 (CYP) 3A4 isozymes (Shet 
et al, 1993; Harris et al, 1994) (Figure 2). In our previous study of
oral paclitaxel in combination with CsA (Meerum Terwogt et al,
1999) we found that after oral drug administration (60 mg/m2) in
combination with CsA the relative contribution of formation of the
metabolite 3′ p-hydroxypaclitaxel was substantially lower than
after i.v. administration, indicating inhibition of CYP 3A4 medi-
ated paclitaxel metabolism by CsA. In the current study of oral
paclitaxel in combination with GF120918 the AUCt ratio of 6α -
hydroxypaclitaxel/3′ p-hydroxypaclitaxel was 1.1, whereas this
ratio was 3.5 when paclitaxel was combined with CsA, revealing a
relative lower contribution of 3′ p-hydroxypaclitaxel following
CsA co-administration. These data also suggest inhibition of the
CYP 3A4 mediated metabolic pathway of paclitaxel by CsA.
Interpretation of the metabolite data should, however, be done with
caution because of the small number of patients enrolled in each
study and the very large interpatient variability in the metabolite
data of paclitaxel. Furthermore, it is important to realise that inhi-
bition of the CYP 3A4 mediated pathway will not necessarily
result in prolonged exposure of active parent compound because
drug not handled by CYP 3A4 might be handled by the CYP 2C8
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Paclitaxel 6a,3´p-dihydroxypaclitaxel
Figure 2 Major metabolic pathways of paclitaxel
Table 2 Pharmacokinetics of oral paclitaxel (120 mg/m2) in combination with
1000 mg GF 120918 and in combination with 15 mg kg–1 cyclosporin A (the
later data were taken from a previously published study (Malingré et al, 2000))
GF120918 Cyclosporin A (CsA)
(n = 6) (n = 3)
AUC (µ M.h) 3.27 ± 1.67 2.55 ± 2.29
Cmax (µ M) 0.36 ± 0.17 0.31 ± 0.13
Tmax (h) 2.8 ± 0.5 3.7 ± 0.7
T > 0.1 µ M (h) 7.5 ± 4.7 7.9 ± 8.0
T > 0.05 µ M (h) 13.5 ± 9.3 13.0 ± 12.746 MM Malingré et al
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pathway, which is, in general, the predominant metabolic pathway
of paclitaxel. 
In a control group of patients treated with oral paclitaxel
(60 mg/m2) but without co-administration of a P-gp blocker, a
study which has been performed previously at our Institute,
bioavailability of single agent oral paclitaxel was determined at
4% (Meerum Terwogt et al, 1998, 1999). In the current study, the
oral bioavailability of paclitaxel (120 mg/m2) in combination with
GF120918 is determined at 30%. However, because i.v. paclitaxel
shows pronounced non-linear pharmacokinetics (Gianni et al,
1995; Sparreboom et al, 1996b) these oral bioavailabilities, calcu-
lated using the AUC of i.v. paclitaxel at a dose of 175 mg/m2, are
underestimated. Using the pharmacokinetic data of i.v. paclitaxel
at dose-levels of 100 mg/m2 and 125 mg/m2 (Huizing et al, 1997)
at which less non-linearity is encountered, the apparent bioavail-
abilities are 6% for oral paclitaxel administered as a single agent
(Meerum Terwogt et al, 1999) and 50% for orally administered
paclitaxel in combination with GF120918. 
An important pharmacokinetic parameter of paclitaxel is the
time-period of exposure above a certain threshold concentration.
Earlier data indicate a strong positive relationship between duration
of the paclitaxel plasma concentration above 0.05 or 0.1 µM and
pharmacological activity (Huizing et al, 1993, 1997; Gianni et al,
1995; Ohtsu et al, 1995). The feasibility of oral paclitaxel adminis-
tration may enable the development of more chronic treatment
schedules with sustained plasma concentrations above these phar-
macological relevant threshold levels. However, it is important to
discuss whether for orally administered paclitaxel these same
threshold concentrations of 0.05 and 0.1 µM are relevant and
should be pursued. Our previous studies of oral paclitaxel have
shown that following oral administration of the drug the co-solvent
Cremophor EL is not absorbed (Meerum Terwogt et al, 1998, 1999;
Malingré et al, 2000). This is important, first of all, because
systemic exposure to Cremophor EL can induce severe hypersen-
sitivity reactions requiring extensive premedication (Dye and
Watkins, 1980; Weiss et al, 1990). Consequently, paclitaxel can be
administered orally without premedication, which has been done in
the current study and without complications. On the other hand,
however, several studies demonstrated that Cremophor EL is a
potent modulator of multidrug resistance in vitro, and it has been
hypothesized that this compound contributes to the clinical activity
of paclitaxel (Woodcock et al, 1990; Webster et al, 1993). However,
the extremely low volume of distribution of Cremophor EL
(Sparreboom et al, 1998), the undetectable levels in (mouse) tissues
(Sparreboom et al, 1996b), and the results in in vivo tumour-
bearing models (Watanabe et al, 1996) suggest that this compound
does not play a role in reversing P-gp mediated resistance to pacli-
taxel in vivo. Absence of systemic Cremophor EL after oral
paclitaxel administration is also important because this compound
is responsible for the non-linear pharmacokinetic behaviour of 
i.v. paclitaxel (Gianni et al, 1995; Sparreboom et al, 1996b).
Cremophor EL increases the affinity of paclitaxel to plasma
components which results in a more than proportional increase in
plasma paclitaxel levels with increasing doses. However, studies in
mice show that these higher ‘total’ drug levels in plasma do not
result in higher drug levels in tissues (Sparreboom et al, 1996a).
This pseudo-non-linearity of i.v. paclitaxel (Van Tellingen et al,
1999) has two important implications for the pharmacology of oral
paclitaxel. First, as mentioned in the discussion above, it will result
in a significant underestimation of the true bioavailability of 
oral paclitaxel. Second, the pseudo-non-linearity of i.v. paclitaxel
implies that after oral administration, when Cremophor EL is not
systemically present, plasma levels of paclitaxel represent a higher
fraction of ‘free’ drug, which will result in enhancement of the
availability of paclitaxel for the (tumour) tissues (Van Tellingen 
et al, 1999). Consequently, the optimal value of the threshold level
may be lower for orally administered paclitaxel compared to 
i.v. paclitaxel; this needs further confirmation. Thus, comparison of
paclitaxel plasma levels after oral and i.v. administration, without
and with Cremophor EL in the systemic circulation, respectively,
should be done with caution. 
In summary, the P-gp inhibitor GF120918 is a good alternative
for CsA administration in enhancing the oral bioavailability of
paclitaxel. Importantly, GF120918 has no known immunosuppres-
sive activity such as CsA and may therefore be a better candidate
for clinical use, especially for repeated administration, than CsA. 
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